Grifols GRFS
NASDAQ GRFS
$8.04 +0.05 (+0.63%)
As of: Aug 21, 2026 · 12:08 PM EDT

Grifols (GRFS) Total Non-Current Liabilities (2009 - 2025)

Grifols' (GRFS) quarterly Total Non-Current Liabilities came in at $11.7 billion in Q4 2025, up 3.27% YoY from $11.4 billion in Q4 2024, and up 3.27% on a QoQ basis from $11.4 billion in Q4 2024.

Grifols (GRFS) Total Non-Current Liabilities (2009 - 2025) Analysis & Trends

Grifols (GRFS) has 17 years of Total Non-Current Liabilities data on file, last reported at $11.7 billion in Q4 2025.

  • Quarterly Total Non-Current Liabilities rose 3.27% year-over-year to $11.7 billion in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $11.7 billion (up 3.27% YoY) and the FY2025 annual result came in at $11.7 billion, up 20873.57% from the prior year.
  • Total Non-Current Liabilities improved to $11.7 billion in Q4 2025, from $11.4 billion in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $12.0 billion in Q4 2023 to a low of $9.7 billion in Q4 2021.
  • A 5-year average of $11.2 billion and a median of $11.5 billion in 2022 frame the typical range for Total Non-Current Liabilities.
  • Annual changes were most pronounced in 2022 — Total Non-Current Liabilities advanced 18.68% — and 2024, when it declined 5.22%.
  • Tracing GRFS's Total Non-Current Liabilities over 5 years: stood at $9.7 billion in 2021, then gained by 18.68% to $11.5 billion in 2022, then advanced by 4.7% to $12.0 billion in 2023, then slipped by 5.22% to $11.4 billion in 2024, then advanced by 3.27% to $11.7 billion in 2025.
  • The last three Total Non-Current Liabilities figures came in at $11.7 billion (Q4 2025), $11.4 billion (Q4 2024), and $12.0 billion (Q4 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Johnson & Johnson 652.95 Bn 632.19 Bn 17.26 Bn 105.99 Bn
2 AbbVie 469.97 Bn 463.40 Bn 12.70 Bn 100.51 Bn
3 Merck 377.05 Bn 369.90 Bn 12.21 Bn 122.23 Bn
4 Novartis Ag 302.66 Bn 294.97 Bn 11.24 Bn 48.34 Bn
5 Astrazeneca 258.09 Bn 253.19 Bn 12.86 Bn 33.91 Bn
6 Amgen 236.99 Bn 223.00 Bn 7.24 Bn 92.80 Bn
7 Gilead Sciences 183.08 Bn 179.90 Bn 6.22 Bn 47.87 Bn
8 Pfizer 160.54 Bn 148.84 Bn 10.94 Bn 100.86 Bn
9 Gsk 106.06 Bn 101.89 Bn 8.24 Bn -30.89 Bn
10 Grifols 5.47 Bn 4.47 Bn - 11.75 Bn

Historic Data

Download Data
DateValue
Dec 31, 2025 11.75 Bn
Dec 31, 2024 11.37 Bn
Dec 31, 2023 12.00 Bn
Dec 31, 2022 11.46 Bn
Dec 31, 2021 9.66 Bn
Dec 31, 2020 8.61 Bn
Sep 30, 2020 8.52 Bn
Mar 31, 2020 8.12 Bn
Dec 31, 2019 8.11 Bn
Sep 30, 2019 8.18 Bn
Dec 31, 2018 7.45 Bn
Sep 30, 2018 7.61 Bn
Jun 30, 2018 7.69 Bn
Mar 31, 2018 8.96 Bn
Dec 31, 2017 7.43 Bn
Jun 30, 2017 7.29 Bn
Dec 31, 2016 5.75 Bn
Sep 30, 2016 5.70 Bn
Jun 30, 2016 5.82 Bn
Dec 31, 2015 5.75 Bn